Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04546399
Title	A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Recruitment	Suspended
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	National Cancer Institute (NCI)
Indications	B-cell acute lymphoblastic leukemia
Therapies	Blinatumomab + Methotrexate + Nivolumab Dexamethasone + Pegaspargase + Vincristine Sulfate Blinatumomab + Methotrexate Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Leucovorin + Mercaptopurine + Methotrexate + Thioguanine + Vincristine Sulfate Blinatumomab + Cytarabine + Dexamethasone + Hydrocortisone Sodium Succinate + Leucovorin + Methotrexate + Nivolumab Blinatumomab + Dexamethasone + Methotrexate Blinatumomab + Cytarabine + Dexamethasone + Hydrocortisone Sodium Succinate + Methotrexate Blinatumomab + Cytarabine + Dexamethasone + Hydrocortisone Sodium Succinate + Methotrexate + Nivolumab Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Pegaspargase + Vincristine Sulfate Blinatumomab + Dexamethasone + Methotrexate + Nivolumab Dexamethasone + Mercaptopurine + Methotrexate + Vincristine Sulfate
Age Groups:	adult \| child
Covered Countries	USA \| CAN \| AUS